Besides, NNT-AS1 was capable of serving as a competing endogenous RNA (ceRNA) by sponging miR-485/BCL9 or miR-203 in cholangiocarcinoma [26, 34], miR-1301-3p/PODXL or miR-496/HMGB1 in bladder cancer [3, 27], miR-142-3p/ZEB1 in breast cancer [19], miR-424/E2F1 or miR-363 in gastric cancer [8, 28], miR-22-3p/YAP1 or miR-129-5p in non-small cell lung cancer [33, 35], and miR-320a in osteosarcoma [31], therefore alteration in cancer cell function resulting from NNT-AS1 downregulation may be rescued by miRNA inhibition. The gene discussed is PODXL; the disease is cancer.